Pacific Bioscience News Today

Dublin, April 19, 2024 (GLOBE NEWSWIRE) -- The

Back when investors willingly took risks on unproven technology firms, ARK Invest (ARKK) attracted investors. Unfortunately, the actively managed ETF manages only $7.3 billion. It lost $2.03 billion in fund flow in the last year and $3.01 billion in ...

The importance of claim construction, and how construing the same term facing a challenge based on different prior art in separate inter partes review proceedings can result in contrary...

The U.S. Court of Appeals for the Federal Circuit (CAFC) in a precedential decision today affirmed two decisions of the Patent Trial and Appeal Board (PTAB) that invalidated some claims and upheld others of a patent owned by Personal Genomics Taiwan, Inc.

Pacific Biosciences of California Inc (NASDAQ: PACB) shares traded higher on Tuesday.

A California federal judge on Monday disqualified all but one of Pacific Biosciences' in-house attorneys and legal support staff from working on a patent infringement case against the biotechnology company, adopting PacBio's proposed measures after the judge disqualified a former Perkins Coie LLP attorney last month.

Third-generation Sequencing Technology Market Analysis and Future Prospects for 2030

Barclays analyst Luke Sergott maintained a Hold rating on Pacific Biosciences (PACB – Research Report) yesterday and set a price target of...

/PRNewswire/ -- The "RNA Analysis Market Size, Share & Trends Analysis Report By Product (Kits & Reagents, Services, Instruments), By Technology (qPCR,...

Dublin, July 06, 2023 (GLOBE NEWSWIRE) -- The "RNA Analysis Market Size, Share & Trends Analysis Report By Product (Kits & Reagents, Services,...